	Application No.	Applicant(s)
Notice of Allowability	10/512 024	HALVEINA APPINIALI IPPALINA
	10/512,024 Examiner	HAJ-YEHIA, ABDULLAH IBRAHIM  Art Unit
	Janes M. Nalas Dr. D	1000
	Jason M. Nolan, Ph.D.	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>10/11/2007</u> .		
2.  The allowed claim(s) is/are 1,2,4-9,12-15,23 and 24 (now 1-14).		
<ul> <li>3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have been received.</li> </ul>		
2. Certified copies of the priority documents have been received in Application No.		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF		
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) I including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	• •
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	
3. Information Disclosure Statements (PTO/SB/08),	7. 🛛 Examiner's Amendr	ment/Comment .
Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit	8. X Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.  Other	

Application/Control Number:

10/512,024 Art Unit: 1626

#### **DETAILED ACTION**

This Office Action is responsive to Applicants Amendment – after Non-Final rejection, filed 10/11/2007. Claims 1, 2, 4-9, 12-24, & 26-28 are pending in the instant application; of which, Claims 1, 4, 8, & 9 are currently amended and Claims 12-22 & 26-28 are withdrawn. Claims 3, 10, 11, & 25 are canceled.

# Response to Amendment

Applicant's amendments with respect to Claims 1, 4, 8, & 9 have been fully considered and are entered. The 112-rejections of Claims 1, 3, 23, & 25 are withdrawn per amendment. The claim objections to Claims 2-9 & 23-25 are withdrawn per amendment.

### Rejoined Inventions

Claims 1, 2, 4-9, 23, & 24 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(b), Claims 12-14: directed to the process of making or using the allowable product and Claims 15: drawn to a composition of the product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Claims 16-22 & 26-28, directed to the invention(s) directed to the process of using the allowable product require all the limitations of an allowable product claim, however have NOT been rejoined. The non-rejoined process claims are drawn to distinct diseases from the rejoined diseases (i.e. melanoma and various cancers).

10/512,024 Art Unit: 1626

Because a claimed invention previously withdrawn from consideration under 37 CFR 1.142 has been rejoined, the restriction requirement between **Group I and Groups II & III** as set forth in the Office action mailed on 03/27/2007 is hereby withdrawn. However the restriction requirement between **Groups I, II, & III** and **Groups IV, V, VI** is maintained. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

#### Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kevin McCarthy on 12/20/2007.

Art Unit: 1626

The application has been amended as follows:

1. In Claim 1, line 2, *after* "A multifunctional β-agonist compound" and *before* "of Formula I:" *delete* "ROS scavenger and NO donor" and *insert* - - having reactive oxygen species (ROS) scavenger groups and nitric oxide (NO) donor groups - -.

2. Delete/Cancel Claims 16-22 & 26-28. These claims are canceled without prejudice; therefore Applicants retain the right to file divisional or continuation applications on the contents thereof.

#### Statement of Reasons for Allowance

The present invention pertains to the compounds of formula I and compositions thereof. The compounds according to formula I are free of the prior art; nothing known in the art anticipates or renders the compounds of the instant application obvious. No other art, besides the work of the inventors contains the bicyclic ring core with a thionitroso-alkylamine substituent. One skilled in the art would be enabled to make and use the compounds taught herein using the teachings of the Specification in conjunction with the teachings in the prior art.

## Conclusion

Claims 1, 2, 4-9, 12-15, 23, & 24 are allowed and are now renumbered as Claims 1-14.

10/512,024 Art Unit: 1626 Page 5

# Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jason M. Nolan, Ph.D. whose telephone number is (571) 272-4356 and electronic mail is Jason.Nolan@uspto.gov. The examiner can normally be reached on Mon - Fri (9:00 - 5:30PM). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jason M. Nolan Patent Examiner Art Unit 1626 (571) 272-4356

Patent Examiner Art Unit 1626

KOMMA SAEED, PILD. -- FILMEN EVALUATE

15 in